Matt Phipps
Stock Analyst at William Blair
(0.61)
# 4,067
Out of 5,033 analysts
23
Total ratings
37.5%
Success rate
-16.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.31 | - | 3 | Oct 17, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $2.32 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $167.91 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $14.77 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $2.51 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $1.37 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $15.07 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $30.54 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $15.19 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $23.05 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.70 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.56 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $43.59 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $26.91 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.53 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $146.63 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $94.44 | - | 1 | Apr 8, 2021 |
Kezar Life Sciences
Oct 17, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.31
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.32
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $167.91
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $14.77
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.51
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.37
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $15.07
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $30.54
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.19
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $23.05
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.70
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.56
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $43.59
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $26.91
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.53
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $146.63
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $94.44
Upside: -